ES2530769T3 - Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno - Google Patents

Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno Download PDF

Info

Publication number
ES2530769T3
ES2530769T3 ES95923042T ES95923042T ES2530769T3 ES 2530769 T3 ES2530769 T3 ES 2530769T3 ES 95923042 T ES95923042 T ES 95923042T ES 95923042 T ES95923042 T ES 95923042T ES 2530769 T3 ES2530769 T3 ES 2530769T3
Authority
ES
Spain
Prior art keywords
antigen
cells
vivo
activation
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95923042T
Other languages
English (en)
Inventor
Edgar G Engleman
Ronald Levy
Frank Hsu
Claudia Benike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of ES2530769T3 publication Critical patent/ES2530769T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Uso de células dendríticas humanas aisladas que se han pulsado con un antígeno in vitro en la producción de un medicamento para activar una respuesta inmunitaria a un antígeno en un paciente humano.
ES95923042T 1994-06-14 1995-06-13 Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno Expired - Lifetime ES2530769T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25977494A 1994-06-14 1994-06-14
PCT/US1995/007461 WO1995034638A1 (en) 1994-06-14 1995-06-13 Methods for in vivo t cell activation by antigen-pulsed dendritic cells

Publications (1)

Publication Number Publication Date
ES2530769T3 true ES2530769T3 (es) 2015-03-05

Family

ID=22986324

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95923042T Expired - Lifetime ES2530769T3 (es) 1994-06-14 1995-06-13 Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno

Country Status (8)

Country Link
EP (1) EP0765386B1 (es)
JP (1) JPH10504284A (es)
AU (1) AU710783B2 (es)
CA (1) CA2192655A1 (es)
DK (1) DK0765386T3 (es)
ES (1) ES2530769T3 (es)
PT (1) PT765386E (es)
WO (1) WO1995034638A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE260971T1 (de) * 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
WO1997022349A1 (en) * 1995-12-20 1997-06-26 The Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP0896506A4 (en) * 1996-03-22 2003-06-18 Univ Yale METHOD FOR INDUCING IMMUNE RESPONSE ABILITY IN A SUBJECT
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6194204B1 (en) 1996-08-02 2001-02-27 Center For Blood Research, Inc. Enrichment of dendritic cells from blood
JP2001509135A (ja) * 1996-10-11 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法
EP1634949B1 (en) 1997-05-08 2010-12-15 Oncothyreon Inc. Method for generating activated T-cells and antigen-pulsed antigen-presenting cells
AU7499498A (en) 1997-05-21 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells
US6713250B1 (en) 1997-08-08 2004-03-30 The Research Foundation Of State University Of New York Identification of human allergens and T-lymphocyte antigens in vitro
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
WO1999042564A2 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US6849452B1 (en) 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2782524B1 (fr) * 1998-08-21 2002-07-19 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
FR2775692B1 (fr) * 1998-03-03 2000-06-16 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
JP2002509716A (ja) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
JP2002517409A (ja) * 1998-06-02 2002-06-18 デンドレオン コーポレイション 抗原提示細胞組成物の調製およびインビボ投与のための方法
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
IT1312570B1 (it) * 1999-05-28 2002-04-22 Genera Spa Metodo per il traferimento di antigeni a cellule dendritiche.
AU779803B2 (en) * 1999-12-03 2005-02-10 Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland, The Dendritic cell-specific antibodies
US6984389B2 (en) * 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
WO2008055354A1 (en) * 2006-11-10 2008-05-15 Université de Montréal Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods
DE102009017827A1 (de) * 2009-04-20 2010-10-21 Sasol Germany Gmbh Verfahren zur Herstellung von verzweigten Kohlenwasserstoffen aus Fettalkoholen und Verwendung derartig hergestellter Kohlenwasserstoffe
BRPI0905536A2 (pt) * 2009-12-16 2011-08-16 Fundacao De Amparo A Pesquisa processo de maturação de células dendrìticas autólogas
EP2678425B1 (en) 2011-02-23 2017-08-23 Kyoto University Method for producing dendritic cells from pluripotent stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells

Also Published As

Publication number Publication date
AU710783B2 (en) 1999-09-30
AU2772595A (en) 1996-01-05
PT765386E (pt) 2015-02-06
EP0765386A4 (en) 1998-01-07
WO1995034638A1 (en) 1995-12-21
EP0765386B1 (en) 2014-12-10
CA2192655A1 (en) 1995-12-21
JPH10504284A (ja) 1998-04-28
DK0765386T3 (en) 2015-01-26
EP0765386A1 (en) 1997-04-02

Similar Documents

Publication Publication Date Title
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
EP2377548A3 (en) Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
CR7786A (es) Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
BR9907189A (pt) Produtos da fração lipìdica do carotenóide de pepino do mar e métodos de uso
GEP20022648B (en) Method for Inducing T Cell Tolerance to a Tissue or Organ Graft
ES2053815T3 (es) Preparacion farmaceutica con liberacion prolongada de una dihidropiridina y un antagonista de un beta-adrenorreceptor y un procedimiento para su preparacion.
ES2051682T3 (es) Un procedimiento para la preparacion de una composicion de liberacion mantenida.
ATE353363T1 (de) Immunstimulierende zusammensetzung und verfahren
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
ES2170259T3 (es) Empleo de lipidos como agentes auxiliares en la obtencion de formas farmaceuticas solidas segun el procedimiento de extrusion en fusion.
ATE491465T1 (de) Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
KR970702733A (ko) 활성물질의 방출 조절용 콜라겐 제제(collagen preparation the controlled release of active substances)
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
SE9003718D0 (sv) Implantat med genomgaaende passage
FI870808A (fi) 9-alfa, 11-beta-substituerade och 11-beta-substituerade estraner.
IT1319275B1 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo.
DK1027063T3 (da) Mannosereceptorbærende cellelinje og antigensammensætning
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
PT1131408E (pt) Acidos oligossacarido-aldonicos e sua utilizacao topica
AR039186A1 (es) Celulas madre indiferenciadas programables de origen monocitaro, su obtencion y uso
HUP0204216A2 (en) A new use of antibodies as vaccines
MX9301746A (es) Nuevos acidos 9-fluor-7-oxo-7h-pirido(1,2,3,-de)(1,4)-benzoxacin-6-carboxilicos y sus esteres, procedimiento para su preparacion y medicamentos que los contienen.